Means To Predict Which HIV+ Infants Will Rapidly Develop AIDS Outlined By Emory University Researchers

November 07, 1996

The identification of a way to single out those HIV+ infants at highest risk for the rapid and aggressive development of AIDS means that doctors may now target these babies for early, powerful therapies, report Emory University researchers in this week's New England Journal of Medicine.

Infants who test positive for HIV can generally be divided into two groups: those in whom AIDS symptoms develop quickly and aggressively -- within the first one to two years of life -- and those in whom symptoms may not appear for a number of years. Until now, doctors have not known conclusively how to predict which HIV+ infants will fall into which category.

Thymus dysfunction was common to the majority of HIV+ infants whose AIDS symptoms progressed rapidly, reports Athena P. Kourtis, M.D., Ph.D., fellow; Andre J. Nahmias, M.D., M.P.H., director, Division of Infectious Diseases, Epidemiology and Immunology, Department of Pediatrics, Emory University School of Medicine; and their colleagues, in their study of 232 infants below six months of age. While the thymus organ, located in the chest, becomes virtually nonfunctional in older age, it serves the important function in children of producing T lymphocyte immune cells. In particular, it produces the CD4+ helper T cells that are depleted by the AIDS virus. It also produces CD8+ cytotoxic T cells. Both types of cells are involved in resistance to HIV, as well as to many other microorganisms.

The researchers postulated that certain strains of the AIDS virus not only deplete mature CD4+ and CD8+ T cells in infants, but also inhibit production of these cells by damaging the thymus. Thus, certain infants would exhibit particularly low levels of CD4+ and CD8+ T cells -- and would develop AIDS symptoms sooner. This tendency to delete both types of T cells is in contrast to what occurs in most other HIV-infected children or adults; usually when the number of CD4+ T cells decreases, the number of CD8+ T cells increases.

An important part of the study was the team's comparison of infants with acquired immune deficiency from HIV to infants with a type of congenital immune deficiency known as the DiGeorge syndrome. Children with DiGeorge syndrome have thymic defects and characteristically low CD4+ and CD8+ T cell counts, as well as low CD5+ B cells. These B cells comprise the majority of immunoglobulin-producing B lymphocytes during gestation and infancy.

The team did indeed find that the number of CD4+ T cells in the 17 HIV-infected infants they characterized with a thymic-defect profile averaged 536 cells per mm3 compared with 2,139 cells per mm3 in 42 HIV-infected infants without the profile and with 3,142 cells per mm3 in 168 control infants who were exposed to, though not infected with, HIV. The team found a similar distribution of CD8+ T cells among the three patient groups: 512 cells per mm3 among the HIV-infected infants with thymus defect profiles compared to 1,214 cells per mm3 among the HIV-infected without the profile and 1,191 cells per mm3 among HIV-exposed controls.

The researchers estimate this subgroup of HIV-infected infants represents about 15 percent of all HIV-infected children. They found that 82 percent of infants in the thymic-defect group would develop AIDS before their first birthday and 38 percent would die; 96 percent would develop AIDS before their second birthday and two-thirds would die. This compares with 34 percent of infants in the no-thymic-defect group developing AIDS by two years and 3 percent dying. The researchers also report that infants in the thymic-defect group were more likely to show abnormalities not only in their cell-mediated immunity but also in their immunoglobulin and antibody production (humoral immunity).

"In this study, we have identified a subpopulation of HIV-infected infants with an immunophenotype resembling that of patients with the DiGeorge syndrome," the authors report. "Our findings suggest that the pathogenesis of disease in this group of infants may involve HIV-induced dysfunction of the thymus...

"Thus, the bimodal pattern of progression in pediatric AIDS may largely be explained by differences in the potential of (certain) HIV strains (with particular affinity to the thymus and which can cross the placenta during gestation) to cause early thymic disruption... "In addition to their pathogenetic importance, our findings have clinical implications that include the need for prompt identification of patients in whom AIDS progresses early and who have the thymic-defect profile," the authors report.

High-risk infants may be identified currently by blood test measurements of the joint distribution of their CD4+ and CD8+ T cells counts, as well as by obtaining CD5+ B cell counts, as early after birth as possible. Newer tests being developed by the Emory group involving the virus may provide other, even earlier, methods of identification.

"The recent recommendations (made by the U.S. Centers for Disease Control and Prevention) for early prophylaxis against P. carinii pneumonia in all HIV-exposed children may prove particularly beneficial in children under the age of six months," the authors conclude. "Therapeutic approaches will need to be more aggressive among these infants, with earlier use of antiviral agents and perhaps even immune reconstitution with thymic transplantation (currently being explored by the Emory group)."

Other Emory authors of the study included Christian Ibegbu, Ph.D.; Francis K. Lee, Ph.D.; Mary K. Sawyer, M.D.; and Steven Nesheim, M.D., all of the Division of Infectious Diseases, Epidemiology and Immunology of Emory's Department of Pediatrics, and W. Scott Clark, Ph.D., of Emory's Rollins School of Public Health.

For more general information on The Robert W. Woodruff Health Sciences Center, call Health Sciences News and Information at 404-727-5686, or send e-mail to

Emory University Health Sciences Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to